相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
Clinical Characteristics of Coronavirus Disease 2019 in China
W. Guan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy
Paola Toniati et al.
AUTOIMMUNITY REVIEWS (2020)
Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Chuan Qin et al.
CLINICAL INFECTIOUS DISEASES (2020)
Association of inflammatory markers with the severity of COVID-19: A meta-analysis
Furong Zeng et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Clinical and immunological features of severe and moderate coronavirus disease 2019
Guang Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Effective treatment of severe COVID-19 patients with tocilizumab
Xiaoling Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
Fei Zhou et al.
LANCET (2020)
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Bingwen Liu et al.
JOURNAL OF AUTOIMMUNITY (2020)
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Giovanni Guaraldi et al.
LANCET RHEUMATOLOGY (2020)
Tocilizumab for the treatment of giant cell arteritis
Michael Schirmer et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2018)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
Trial of Tocilizumab in Giant-Cell Arteritis
J. H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
分享论文
